An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

Conditions: Achondroplasia
Interventions: Drug: Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Sponsors: BioMarin Pharmaceutical
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 14, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments